Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms RUXO-BEAT
- 02 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 05 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 07 Jul 2015 New trial record